MG
PNT

Michael Gelband’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Michael Gelband’s Portfolio PNT Stock Details PNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-17,014
Closed -$154K – 2266
2023
Q2 		$154K Buy
+17,014
New +$150K ﹤0.01% 1715
2022
Q2 		– Sell
-240,515
Closed -$1.92M – 2603
2022
Q1 		$1.92M Buy
240,515
+85,481
+55% +$543K 0.02% 800
2021
Q4 		$868K Buy
+155,034
New +$1.16M 0.01% 1150

Other funds holding PNT

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Michael Gelband's PNT Position: Q3 2023 in Review

Michael Gelband sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q3 2023, closing a stake of 17,014 shares — an estimated $154K sold.

Michael Gelband first reported a position in PNT in Q4 2021 and held it in 3 quarters. The position peaked at $1.92M in Q1 2022. 125 funds tracked by Wall St. Rank hold PNT as of Q3 2023.

  • Michael Gelband reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Michael Gelband sold 17,014 POINT Biopharma Global Inc. Common Stock shares in Q3 2023, an estimated $154K.
  • Michael Gelband first reported a position in POINT Biopharma Global Inc. Common Stock in Q4 2021 and held it in 3 quarters.
  • Michael Gelband's POINT Biopharma Global Inc. Common Stock position peaked at $1.92M in Q1 2022.
  • 125 funds tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q3 2023.

Based on ExodusPoint Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.